Female Patient, Aged 56 Years (Patient 2).

<p>Coronal (a) and transaxial (b) localizing image planned along the course of the portal vein (line). Based on these images, a phase-contrast enconding sequence was planned perpendicular to the course of the portal vein (line). c: Portal vein (arrowhead) velocity-encoded phase-contrast image. d: Portal vein (arrow) magnitude image.</p

Modification of Blood flow measured on Magnetic Resonance Imaging under sorafenib therapy and after withdrawal.

<p>(a) Portal Venous flow, (b) Azygos Venous flow, and (c) Abdominal Aortic Flow.</p

Venous Flow at base line.

<p>Results are expressed as mean ± SD.</p

Patients Characteristics.

<p>Patients Characteristics.</p

Study timelines.

<p>Study timelines.</p

Comparisons between patients with and without sarcopenia.

<p> <i>SD, standard deviation; ECOG, Eastern Cooperative Oncology Group Criteria Performance Status; BMI, Body Mass Index [weight(kg)/height(m)²]; BSA, Body Surface Area.</i></p><p>(d) Calculated from regression equation: whole lean body mass (kg) = 0.30×[[skeletal muscle at L3 using CT (cm²)]+6.06].</p><p>(b) Hypertension was not considered as a dose limiting toxicity.</p

Patients selection for the present study.

<p>Patients selection for the present study.</p

Baseline characteristics of cirrhotic patients treated with sorafenib.

<p> <i>ECOG, Eastern Cooperative Oncology Group Criteria Performance Status; BMI, Body Mass Index (weight/height²).</i></p><p>(a) Calculated from the regression equation: whole lean body mass (kg) = 0.30×[[skeletal muscle at L3 using CT (cm²)]+6.06]</p><p>(b) Total tissue sectional area at L3 (cm²)</p><p>(c) Lumbar tissue index: area/height (cm²/m²).</p

Histological analysis of the swine esophagus after Masson's trichrome staining.

<p>A: swine from the control group, sacrificed at day 14, with major fibrosis measured at 1.79 mm and thick granulation tissue measured at 0.65 mm, original magnification 12.5x; B: swine from the AM 1 group (amniotic membrane graft and early sacrifice scheduled at day 14), without esophageal stricture, with minimal fibrosis and mostly granulation tissue, measured at 0.94 mm, original magnification 10x; C: swine from the AM 2 group sacrificed at day 21, exhibiting major re-epithelialization measured at 8.06 mm, original magnification 15x; D: granulation tissue with features of acute inflammation, as observed in the early phase of esophageal wounds: high cell density, predominance of polynuclear cells (black arrow), fibrino-leucocytary network (blue arrow), and typical palissadic vascular growth (red arrows), original magnification 400x.</p

Immunohistochemistry staining with anti-αSMA antibody, original magnification ×200.

<p>Strong signal (brown spots) attesting high myofibroblastic activity (panel A, black arrow) and high vascular density (panel A, white arrow) in control (A); nearly absent signal in MA-treated swine (B).</p